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devices to patients may have a positive impact on treatment outcomes. The aim of
this study was to better understand the preferences of MS patients for attributes of
self-injection devices. METHODS: A discrete choice experiment (DCE) survey was
developed on the basis of a review of published literature. The attributes identified
for inclusion in the survey were: ease of use; comfort of use; presence of additional
functions, needle visibility; practicality and efficacy. Choice sets were presented as pairs
of hypothetical treatments based upon a fractional factorial design. One-hundred
device-using MS patients completed the survey online. Analysis was conducted
using a mixed-logit approach RESULTS: Analysis of the DCE data revealed that all
attributes significantly predicted treatment choice. As anticipated, efficacy exhib-
ited the largest effect on treatment selection and this provided context for under-
standing themagnitude of impact for the other attributes. Reducing the discomfort
associated with device use and eliminating the necessity for assembly or drug
reconstitution were highly valued by patients. The addition of reminder and time-
stamping functions, improved needlestick injury prevention and a reduction in
device size were secondary concerns but still deemed desirable. CONCLUSIONS:
Although efficacy is of primary importance to MS patients, the characteristics of
drug delivery devices can play an important role in treatment decision-making.
The findings suggest that there is significant potential value in developing self-
injection devices that are not only efficacious but also convenient and comfortable
to use. Reducing barriers to adherence could potentially translate into improved
treatment outcomes for patients with MS.
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OBJECTIVES: While a variety of knee-specific instruments currently exist, no pa-
tient-reported outcome (PRO)measures correlate functionwith improved stability,
motion, satisfaction, and confidence. The objective of our study was to address the
identified gap in available PROs assessing this phenomenon of a “normal” knee
following primary TKA.METHODS: A conceptual model linking the impact of clin-
ical mechanics to hypothesized functional outcomes was generated following a
literature review of available assessment tools. Participants aged 18 to 80 who had
undergone TKA within the past 10 to 18 months were identified through clinical
sites to participate in Phase 1) focus groups, or Phase 2) in-depth interviews. Par-
ticipants were asked to describe experiences with their knee replacement and
general questions about how their knee feels now, since they had the surgery,
followed by cognitive debriefing of the draft items. Specific inclusion and exclusion
criteria were developed in addition to a semi-structured interview guide. Constant
comparative analysis was employed to identify key points and compared across all
results to observe themes in participant experiences. RESULTS: Results from the
first phase of the project indicated that the concepts of confidence, stability, and
satisfaction in their replacement kneewhenperforming activities requiring certain
motions were felt to be distinct from each other and important in the patients’
assessment of their TKA. Phase 2 efforts yielded a final version of the PKIP scale
containing 9 items assessing the broader concepts of stability, confidence and
satisfaction in association with activities. Both a pre and post-surgical version of
themeasurewere created.CONCLUSIONS:Results of this qualitative study support
the use of the PKIP to assess performance following primary TKA. Psychometric
evaluation of the PKIP is planned.
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OBJECTIVES: It is not clearly establishedwhether percutaneous coronary interven-
tion (PCI) provides similar incremental benefit in terms of health related quality of
life (HRQoL) among all patients.METHODS:We analyzed 795 consecutive patients
undergoing PCI at our institution. Health outcomes was estimated in terms of
quality adjusted life years (QALYs) gainedmeasured using EQ-5D at baseline, 6 and
12 months after PCI. Change in QALY at 1 year was compared between different
subgroups. The Canadian Cardiac Society (CCS) Classification of angina symptom
was used. RESULTS: Overall mean EQ-5D utility scores were higher at 6 (0.860.22)
and 12months (0.790.21) than at baseline (0.440.42) andmeanQALY gainedwas
0.39. Patients who underwent rescue PCI (QALY gain 0.74), primary PCI for STEMI
(0.49) and left main coronary artery intervention (0.57) experienced the highest
gain in QALY. There was progressive increase in QALY gain for patients with CCS 1
(0.24), 2 (035), 3 (0.45) and 4 (0.49) angina symptoms (p0.01). Females (0.43) expe-
rienced greater gain in QALY than males (0.38). QALY gain was higher in patients
who had PCI to 3- (0.43) than in 2- (0.40) and 1-vessel (0.39, p0.01). There were no
differences in QALY gain between patients 40-60, 60-80 and80 years old. Patients
who experienced the least QALY gain had a history of renal failure (0.24), previous
PCI (0.3), failed index PCI (0.27) and chronic total occlusion intervention (0.31).
Patients who required repeat PCI during follow-up had lower QALY gain (0.32)
compared to those without (0.40). CONCLUSIONS: Despite overall improvement in
health status, there was significant variation in the magnitude of quality of life
improvement among different patient subgroups after PCI.
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OBJECTIVES: To determine the effect of adjusting colorectal-cancer (CRC) screen-
ingwillingness-to-pay (WTP) estimates for uptake bias fromyea-saying in a choice-
format conjoint-analysis study.Yea-saying refers to a tendency to express agree-
ment regardless of one’s actual views when responding to hypothetical questions.
Screening tests offer an opportunity to compare stated and actual uptake rates.
METHODS:Adults aged 45-70 yearswith no history of CRC and physicians from the
United States and Canada completed aweb-enabled choice-format conjoint survey
that presented subjects with pairs of profiles for screening tests. Test features
included test type, frequency, accuracy, and cost. Each test-preference question
was followed by a question asking if the respondent preferred no screening to the
chosen test. A bivariate probit model combined data from both questions. Pre-
dicted WTP conditional on purchasing a test and societal expected WTP adjusted
for uptake probabilitywere estimated for both samples. RESULTS:A total of 501 and
1,087 adults fromCanada and theUnited States respectively, and 100 physicians from
both countries completed the survey. Patients opted for a screening test in about 70%
of the questions. Physicians expected their patients to opt for a screening only 50% of
the time, which is the same as the observed uptake rate. For any given screening test,
physicians’ surrogateWTP values were significantly less than patients’ values. More-
over, patients had significantly larger divergences between conditional and expected
WTPmeasures. The US patient expectedWTP for colonoscopy, adjusted for yea-say-
ing bias in predicted uptake, was $435, which was 29% smaller than the unadjusted
expected WTP. CONCLUSIONS: If stated-preference subjects choose testing more
frequently than they would if actually offered the hypothetical alternatives, the up-
wardly biaseduptake estimatesdistort societalWTPmeasures.Minimizing incentives
for yea-saying, detecting potential bias, and adjusting resulting WTP estimates is a
high priority for stated-preference research.
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OBJECTIVES: To explore the ways in which hospital payments can be used to
encourage cost-effective use of health technology.METHODS: A survey of the de-
velopers of hospital payment systemswas conducted in 14 jurisdictions in order to
ascertain if and how existing payment systems facilitate the adoption of new tech-
nologies, whether evidence of value (eg therapeutic benefit, cost-effectiveness) is
considered when determining codes/ tariffs, and in what ways payment systems
could be adjusted to link payment levels more closely to evidence on value for
money. RESULTS: Around 50% of the jurisdictions had developed their own pay-
ment classifications, as opposed to importing/adapting a system fromelsewhere. A
minority had created new codes/tariffs outside of a general update in response to a
new technology. Three jurisdictions used evidence of value when creating new
codes/tariffs, although they tended to only consider therapeutic benefit, not cost-
effectiveness. The main barriers to using evidence in creating new codes/tariffs
were the lack of a clear mechanism to do so, lack of standardization in the collec-
tion of hospital cost data and unclear or unavailable clinical evidence. Around 70%
of jurisdictions had used special payments, outside of the standard codes/tariffs, in
response to specific new technologies and 50%used evidence of valuewhen setting
payment levels. In the case of special payments, consideration of evidence of both
therapeutic benefit and cost-effectiveness was more common. Overall, respon-
dents felt that hospital payment systems had only amodest tomoderate impact on
the uptake of new technologies, due primarily to the time taken in establishing new
codes/tariffs, or negotiating special payments. CONCLUSIONS: Hospital payment
systems have the potential to encourage the cost-effective use of new health tech-
nologies. More attention, however, is needed regarding the procedures for updat-
ing codes/tariffs or negotiating special payments, and in particular the ways of
considering evidence of value.
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OBJECTIVES: This study evaluates the impact on market dynamics of applying
existing Health Technology Assessment (HTA) methodologies to medical devices.
METHODS: Using a case study on drug-eluting stents (DES), we examine whether
the economic characteristics of medical devices introduce particular challenges to
the application of HTA and whether the experience of DESs suggests directions for
policy formulation.RESULTS:The case study found amarket that encourages rapid
competition, leading to value for the end user though price competition. The ap-
plication of existing HTA methods has the potential to disrupt this dynamic and
reduce the rewards of medical devices to innovators - through higher evidence
requirements on initial entrants and market dynamics that subsequently drive a
reduction in prices. A cycle of price reductions results because the comparator
price of the old technology is reduced as a consequence of ‘disinvestment’ follow-
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